Confidential Materials omitted and filed separately with theTarget Discovery, Research Collaboration and Option Agreement • March 12th, 2018 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 12th, 2018 Company Industry JurisdictionThis Target Discovery, Research Collaboration and Option Agreement (this “Agreement”) is made effective as of January 8, 2018 (the “Effective Date”) by and between Syros Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 620 Memorial Drive, Suite 300, Cambridge, Massachusetts 02139 (“Syros”) and Incyte Corporation, a Delaware corporation having its principal place of business at 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (“Incyte”). Syros and Incyte are each referred to herein by name or as a “Party” or, collectively, as “Parties”.